These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 8630956)

  • 1. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome.
    Joshi MG; Lee AK; Loda M; Camus MG; Pedersen C; Heatley GJ; Hughes KS
    Cancer; 1996 Feb; 77(3):490-8. PubMed ID: 8630956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of clinical, pathological status, hormone receptor and C-erbB-2 oncoprotein in breast cancer patients.
    Aryandono T; Harijadi ; Ghozali A
    Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():600-6. PubMed ID: 10895217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
    Middleton LP; Amin M; Gwyn K; Theriault R; Sahin A
    Cancer; 2003 Sep; 98(5):1055-60. PubMed ID: 12942575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
    McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
    Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
    Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of axillary lymph node metastases in patients with T1 breast carcinoma.
    Barth A; Craig PH; Silverstein MJ
    Cancer; 1997 May; 79(10):1918-22. PubMed ID: 9149018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients.
    Kwiatkowska E; Teresiak M; Filas V; Karczewska A; Breborowicz D; Mackiewicz A
    Clin Cancer Res; 2003 Oct; 9(12):4452-9. PubMed ID: 14555518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R; van der Groep P; Greijer AE; Shvarts A; Meijer S; Pinedo HM; Semenza GL; van Diest PJ; van der Wall E
    Cancer; 2003 Mar; 97(6):1573-81. PubMed ID: 12627523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical detection of p53 protein expression in breast cancer in young Kuwaiti women.
    Temmim L; Baker H; Sinowatz F
    Anticancer Res; 2001; 21(1B):743-8. PubMed ID: 11299837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.
    Tan P; Cady B; Wanner M; Worland P; Cukor B; Magi-Galluzzi C; Lavin P; Draetta G; Pagano M; Loda M
    Cancer Res; 1997 Apr; 57(7):1259-63. PubMed ID: 9102210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers.
    Moreno A; Lloveras B; Figueras A; Escobedo A; Ramon JM; Sierra A; Fabra A
    Mod Pathol; 1997 Nov; 10(11):1088-92. PubMed ID: 9388058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.
    Bebenek M; Bar JK; Harlozinska A; Sedlaczek P
    Anticancer Res; 1998; 18(1B):619-23. PubMed ID: 9568187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-erbB-2, p53 protein expression and steroid hormone receptors in breast carcinomas: an immunohistochemical study.
    Yokota T; Imamura M; Teshima S; Suzuki H; Tezuka F; Kikuchi S; Kunii Y; Yamauchi H
    Anticancer Res; 1999; 19(5B):4007-12. PubMed ID: 10628345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Breast cancer: prognostic value of flow cytometry and hormone receptors. Apropos of a Lebanese series of patients].
    Aftimos G; Trak-Smayra V; Moacdieh-Rehayel L
    J Med Liban; 2000; 48(1):8-17. PubMed ID: 10881437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
    Malamou-Mitsi VD; Syrrou M; Georgiou I; Pagoulatos G; Agnantis NJ
    J Exp Clin Cancer Res; 1999 Sep; 18(3):357-61. PubMed ID: 10606182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor.
    Chang J; Clark GM; Allred DC; Mohsin S; Chamness G; Elledge RM
    Cancer; 2003 Feb; 97(3):545-53. PubMed ID: 12548595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
    Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
    Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.